Literature DB >> 35615331

The Mediterranean Journal of Hematology and Infectious Diseases: A New Milestone and a Hope for Researchers in Third World Countries.

Nawfal R Hussein1.   

Abstract

Entities:  

Year:  2022        PMID: 35615331      PMCID: PMC9083949          DOI: 10.4084/MJHID.2022.035

Source DB:  PubMed          Journal:  Mediterr J Hematol Infect Dis        ISSN: 2035-3006            Impact factor:   3.122


× No keyword cloud information.
To the editor. We learned with pleasure that The Mediterranean Journal of Hematology and Infectious Diseases had hit a new milestone by obtaining an impact factor of 2.576. We want to congratulate you on this achievement. From our point of view, in a country with poor resources and enthusiastic researchers, the MJHID was a shelter for our papers. This Journal provides three advantages for us. Firstly, English language weakness does not influence the decision, and secondly, it provides a good guide to the researcher to build a good quality project. Thirdly, the communication with the Editor is straightforward without obstacles. Utilizing such advantages, we could have published good papers in the MJHID, gaining readers’ attention and recording good citations.1–5 It is believed that the advantages the MJHID provided to authors have played a role in hitting such a milestone. The new Journal’s achievement should not change its standards to continue encouraging us all the researchers of low-income countries. Therefore, we believe that hitting a new milestone should drive you to increase the help to researchers in the low-income research setting and where the research resources are sparse. We suggest the Journal establish a mentoring committee to help such researchers meet international standards and make necessary amendments to the projects rather than rejecting the papers in the first screening and/or revision round. Finally, in a world full of challenges for researchers who work in an environment that does not appreciate and support research, we hope to support and provide a platform that makes our voice heard.
  5 in total

1.  The Risk of SARS-CoV-2 Reinfection in Duhok city, Kurdistan Region of Iraq.

Authors:  Nawfal R Hussein; Brisik H Rashad; Lokman A Almizori; Shawkat Sabri Yousif; Ahmed Tayar Sadeeq; Yaseen Rashad Abdulkareem; Alan Mobarek Mahmood; Zhiyan K Salih
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

2.  The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy.

Authors:  N R Hussein
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

3.  Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection.

Authors:  Nawfal R Hussein; Zana S M Saleema; Qais H Abd
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-05-01       Impact factor: 2.576

4.  The Efficacy and Safety of Intralesional Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis in Children under the Age of Two Years.

Authors:  Nawfal R Hussein; Ibrahim A Naqid; Haval M Salih
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-05-01       Impact factor: 2.576

5.  A Retrospective Descriptive Study Characterizing Coronavirus Disease Epidemiology among People in the Kurdistan Region, Iraq.

Authors:  Nawfal R Hussein; Ibrahim A Naqid; Zana Sidiq M Saleem
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.